Inter- and intrafractional 4D dose accumulation for evaluating ΔNTCP robustness in lung cancer.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
05 2023
Historique:
received: 30 11 2022
revised: 12 01 2023
accepted: 18 01 2023
medline: 25 4 2023
pubmed: 28 1 2023
entrez: 27 1 2023
Statut: ppublish

Résumé

Model-based selection of proton therapy patients relies on a predefined reduction in normal tissue complication probability (NTCP) with respect to photon therapy. The decision is necessarily made based on the treatment plan, but NTCP can be affected when the delivered treatment deviates from the plan due to delivery inaccuracies. Especially for proton therapy of lung cancer, this can be important because of tissue density changes and, with pencil beam scanning, the interplay effect between the proton beam and breathing motion. In this work, we verified whether the expected benefit of proton therapy is retained despite delivery inaccuracies by reconstructing the delivered treatment using log-file based dose reconstruction and inter- and intrafractional accumulation. Additionally, the importance of two uncertain parameters for treatment reconstruction, namely deformable image registration (DIR) algorithm and α/β ratio, was assessed. The expected benefit or proton therapy was confirmed in 97% of all studied cases, despite regular differences up to 2 percent point (p.p.) NTCP between the delivered and planned treatments. The choice of DIR algorithm affected NTCP up to 1.6 p.p., an order of magnitude higher than the effect of α/β ratio. For the patient population and treatment technique employed, the predicted clinical benefit for patients selected for proton therapy was confirmed for 97.0% percent of all cases, although the NTCP based proton selection was subject to 2 p.p. variations due to delivery inaccuracies.

Sections du résumé

BACKGROUND AND PURPOSE
Model-based selection of proton therapy patients relies on a predefined reduction in normal tissue complication probability (NTCP) with respect to photon therapy. The decision is necessarily made based on the treatment plan, but NTCP can be affected when the delivered treatment deviates from the plan due to delivery inaccuracies. Especially for proton therapy of lung cancer, this can be important because of tissue density changes and, with pencil beam scanning, the interplay effect between the proton beam and breathing motion.
MATERIALS AND METHODS
In this work, we verified whether the expected benefit of proton therapy is retained despite delivery inaccuracies by reconstructing the delivered treatment using log-file based dose reconstruction and inter- and intrafractional accumulation. Additionally, the importance of two uncertain parameters for treatment reconstruction, namely deformable image registration (DIR) algorithm and α/β ratio, was assessed.
RESULTS
The expected benefit or proton therapy was confirmed in 97% of all studied cases, despite regular differences up to 2 percent point (p.p.) NTCP between the delivered and planned treatments. The choice of DIR algorithm affected NTCP up to 1.6 p.p., an order of magnitude higher than the effect of α/β ratio.
CONCLUSION
For the patient population and treatment technique employed, the predicted clinical benefit for patients selected for proton therapy was confirmed for 97.0% percent of all cases, although the NTCP based proton selection was subject to 2 p.p. variations due to delivery inaccuracies.

Identifiants

pubmed: 36706960
pii: S0167-8140(23)00026-9
doi: 10.1016/j.radonc.2023.109488
pii:
doi:

Substances chimiques

Protons 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109488

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.

Auteurs

Andreas Smolders (A)

Centre for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland; Department of Physics, ETH Zurich, Zurich, Switzerland. Electronic address: andreas.smolders@psi.ch.

Adriaan C Hengeveld (AC)

Department of Radiation Oncology, University Medical Center of Groningen, University of Groningen, Groningen, The Netherlands.

Stefan Both (S)

Department of Radiation Oncology, University Medical Center of Groningen, University of Groningen, Groningen, The Netherlands.

Robin Wijsman (R)

Department of Radiation Oncology, University Medical Center of Groningen, University of Groningen, Groningen, The Netherlands.

Johannes A Langendijk (JA)

Department of Radiation Oncology, University Medical Center of Groningen, University of Groningen, Groningen, The Netherlands.

Damien C Weber (DC)

Centre for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland; Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland; Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Anthony J Lomax (AJ)

Centre for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland; Department of Physics, ETH Zurich, Zurich, Switzerland.

Francesca Albertini (F)

Centre for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland.

Gabriel Guterres Marmitt (G)

Department of Radiation Oncology, University Medical Center of Groningen, University of Groningen, Groningen, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH